Dual modality imaging of a novel rat model of ovarian carcinogenesis

Elizabeth M. Kanter, Ross M. Walker, Samuel L. Marion, Molly Brewer, Patricia B Hoyer, Jennifer K Barton

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Ovarian cancer is the fifth leading cause of cancer death in women, in part because of the limited knowledge about early stage disease. We develop a novel rat model of ovarian cancer and perform a pilot study to examine the harvested ovaries with complementary optical imaging modalities. Rats are exposed to repeated daily dosing (20 days) with 4-vinylcyclohexene diepoxide (VCD) to cause early ovarian failure (model for postmenopause), and ovaries are directly exposed to 7,12-dimethylbenz(a)anthracene (DMBA) to cause abnormal ovarian proliferation and neoplasia. Harvested ovaries are examined with optical coherence tomography (OCT) and light-induced fluorescence (LIF) at one, three, and five months post-DMBA treatment. VCD causes complete ovarian follicle depletion within 8 months after onset of dosing. DMBA induces abnormal size, cysts, and neoplastic changes. OCT successfully visualizes normal and abnormal structures (e.g., cysts, bursa, follicular remnant degeneration) and the LIF spectra show statistically significant changes in the ratio of average emission intensity at 390:450 nm between VCD-treated ovaries and both normal cycling and neoplastic DMBA-treated ovaries. Overall, this pilot study demonstrates the feasibility of both the novel animal model for ovarian cancer and the ability of optical imaging techniques to visualize ovarian function and health.

Original languageEnglish (US)
Article number041123
JournalJournal of Biomedical Optics
Volume11
Issue number4
DOIs
StatePublished - Jul 2006

Fingerprint

9,10-Dimethyl-1,2-benzanthracene
ovaries
rats
Rats
Ovary
Carcinogenesis
Optical tomography
Imaging techniques
cancer
Ovarian Neoplasms
Fluorescence
cysts
causes
Optical Imaging
Optical Coherence Tomography
Anthracene
tomography
Follicular Cyst
Animals
Postmenopause

Keywords

  • 4-vinylcyclohexene diepoxide
  • 7,12-dimethylbenz(a) anthracene
  • Light-induced fluorescence
  • Menopause
  • Optical coherence tomography
  • Ovarian cancer

ASJC Scopus subject areas

  • Biomedical Engineering
  • Biomaterials
  • Electronic, Optical and Magnetic Materials
  • Atomic and Molecular Physics, and Optics
  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology
  • Clinical Biochemistry

Cite this

Dual modality imaging of a novel rat model of ovarian carcinogenesis. / Kanter, Elizabeth M.; Walker, Ross M.; Marion, Samuel L.; Brewer, Molly; Hoyer, Patricia B; Barton, Jennifer K.

In: Journal of Biomedical Optics, Vol. 11, No. 4, 041123, 07.2006.

Research output: Contribution to journalArticle

Kanter, Elizabeth M. ; Walker, Ross M. ; Marion, Samuel L. ; Brewer, Molly ; Hoyer, Patricia B ; Barton, Jennifer K. / Dual modality imaging of a novel rat model of ovarian carcinogenesis. In: Journal of Biomedical Optics. 2006 ; Vol. 11, No. 4.
@article{675f55bdd9fc49fd9c2199d74ca662a5,
title = "Dual modality imaging of a novel rat model of ovarian carcinogenesis",
abstract = "Ovarian cancer is the fifth leading cause of cancer death in women, in part because of the limited knowledge about early stage disease. We develop a novel rat model of ovarian cancer and perform a pilot study to examine the harvested ovaries with complementary optical imaging modalities. Rats are exposed to repeated daily dosing (20 days) with 4-vinylcyclohexene diepoxide (VCD) to cause early ovarian failure (model for postmenopause), and ovaries are directly exposed to 7,12-dimethylbenz(a)anthracene (DMBA) to cause abnormal ovarian proliferation and neoplasia. Harvested ovaries are examined with optical coherence tomography (OCT) and light-induced fluorescence (LIF) at one, three, and five months post-DMBA treatment. VCD causes complete ovarian follicle depletion within 8 months after onset of dosing. DMBA induces abnormal size, cysts, and neoplastic changes. OCT successfully visualizes normal and abnormal structures (e.g., cysts, bursa, follicular remnant degeneration) and the LIF spectra show statistically significant changes in the ratio of average emission intensity at 390:450 nm between VCD-treated ovaries and both normal cycling and neoplastic DMBA-treated ovaries. Overall, this pilot study demonstrates the feasibility of both the novel animal model for ovarian cancer and the ability of optical imaging techniques to visualize ovarian function and health.",
keywords = "4-vinylcyclohexene diepoxide, 7,12-dimethylbenz(a) anthracene, Light-induced fluorescence, Menopause, Optical coherence tomography, Ovarian cancer",
author = "Kanter, {Elizabeth M.} and Walker, {Ross M.} and Marion, {Samuel L.} and Molly Brewer and Hoyer, {Patricia B} and Barton, {Jennifer K}",
year = "2006",
month = "7",
doi = "10.1117/1.2236298",
language = "English (US)",
volume = "11",
journal = "Journal of Biomedical Optics",
issn = "1083-3668",
publisher = "SPIE",
number = "4",

}

TY - JOUR

T1 - Dual modality imaging of a novel rat model of ovarian carcinogenesis

AU - Kanter, Elizabeth M.

AU - Walker, Ross M.

AU - Marion, Samuel L.

AU - Brewer, Molly

AU - Hoyer, Patricia B

AU - Barton, Jennifer K

PY - 2006/7

Y1 - 2006/7

N2 - Ovarian cancer is the fifth leading cause of cancer death in women, in part because of the limited knowledge about early stage disease. We develop a novel rat model of ovarian cancer and perform a pilot study to examine the harvested ovaries with complementary optical imaging modalities. Rats are exposed to repeated daily dosing (20 days) with 4-vinylcyclohexene diepoxide (VCD) to cause early ovarian failure (model for postmenopause), and ovaries are directly exposed to 7,12-dimethylbenz(a)anthracene (DMBA) to cause abnormal ovarian proliferation and neoplasia. Harvested ovaries are examined with optical coherence tomography (OCT) and light-induced fluorescence (LIF) at one, three, and five months post-DMBA treatment. VCD causes complete ovarian follicle depletion within 8 months after onset of dosing. DMBA induces abnormal size, cysts, and neoplastic changes. OCT successfully visualizes normal and abnormal structures (e.g., cysts, bursa, follicular remnant degeneration) and the LIF spectra show statistically significant changes in the ratio of average emission intensity at 390:450 nm between VCD-treated ovaries and both normal cycling and neoplastic DMBA-treated ovaries. Overall, this pilot study demonstrates the feasibility of both the novel animal model for ovarian cancer and the ability of optical imaging techniques to visualize ovarian function and health.

AB - Ovarian cancer is the fifth leading cause of cancer death in women, in part because of the limited knowledge about early stage disease. We develop a novel rat model of ovarian cancer and perform a pilot study to examine the harvested ovaries with complementary optical imaging modalities. Rats are exposed to repeated daily dosing (20 days) with 4-vinylcyclohexene diepoxide (VCD) to cause early ovarian failure (model for postmenopause), and ovaries are directly exposed to 7,12-dimethylbenz(a)anthracene (DMBA) to cause abnormal ovarian proliferation and neoplasia. Harvested ovaries are examined with optical coherence tomography (OCT) and light-induced fluorescence (LIF) at one, three, and five months post-DMBA treatment. VCD causes complete ovarian follicle depletion within 8 months after onset of dosing. DMBA induces abnormal size, cysts, and neoplastic changes. OCT successfully visualizes normal and abnormal structures (e.g., cysts, bursa, follicular remnant degeneration) and the LIF spectra show statistically significant changes in the ratio of average emission intensity at 390:450 nm between VCD-treated ovaries and both normal cycling and neoplastic DMBA-treated ovaries. Overall, this pilot study demonstrates the feasibility of both the novel animal model for ovarian cancer and the ability of optical imaging techniques to visualize ovarian function and health.

KW - 4-vinylcyclohexene diepoxide

KW - 7,12-dimethylbenz(a) anthracene

KW - Light-induced fluorescence

KW - Menopause

KW - Optical coherence tomography

KW - Ovarian cancer

UR - http://www.scopus.com/inward/record.url?scp=33751321431&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33751321431&partnerID=8YFLogxK

U2 - 10.1117/1.2236298

DO - 10.1117/1.2236298

M3 - Article

C2 - 16965151

AN - SCOPUS:33751321431

VL - 11

JO - Journal of Biomedical Optics

JF - Journal of Biomedical Optics

SN - 1083-3668

IS - 4

M1 - 041123

ER -